We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,346

Government moves to legislate to increase generic and biosimilar medicine uptake and cut medicine prices
  • Bird & Bird
  • Australia
  • July 24 2017

Australia has long lagged behind the USA and UK in its use of generic pharmaceuticals - only around 58 of medicines dispensed in Australia are the


Pharma and Biologics Disputes in CanadaBig Changes for Big and Small Molecule Litigation
  • Bennett Jones LLP
  • Canada
  • July 20 2017

The patent litigation that propels generic and biosimilar products to market will soon change dramatically. July 15, 2017, marked the release of


FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 19 2017

The FDA’s Oncologic Drug Advisory Committee (“ODAC”) held a public meeting on Wednesday, July 12, 2017, to consider Novartis’ biologic license


Boehringer Ingelheim Prevails in IPR Against AbbVie’s ’135 Humira Patent
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 18 2017

Boehringer Ingelheim International GMBH and Boehringer Ingelheim Pharmaceuticals, Inc. (“Boehringer Ingelheim”) have prevailed in two inter parts


You Can Dance If You Want To
  • Sterne Kessler Goldstein & Fox
  • USA
  • July 18 2017

In borrowing a page from the '80s band "Men Without Hats," on June 12, 2017, the U.S. Supreme Court brought greater certainty for both biosimilar


Coherus Challenges One AbbVie Humira Patent In Four PTAB Proceedings
  • Foley & Lardner LLP
  • USA
  • July 18 2017

I’ve written previously about sequential PTAB challenges to the same patent, but the dispute between Coherus Biosciences Inc. and AbbVie


Amendments to Canada’s patent linkage provisions relating to generic and biosimilar market approval
  • DLA Piper LLP
  • Canada
  • July 17 2017

On July 14, 2017, long-awaited amendments to Canada's patent linkage provisions (the Patented Medicines (Notice of Compliance) Regulations


ANDA & Biosimilar and the Law
  • Foley & Lardner LLP
  • USA
  • July 10 2017

Welcome to Foley & Lardner’s Summer 2017 edition of ANDA & Biosimilar and the Law. In our Legal Developments section, we report on a number of


The Travails of the First U.S. EPO Biosimilar
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • July 10 2017

Pfizer’s proposed biosimilar of Amgen’s Epogen and Johnson & Johnson’s Procrit (epoetin alfa) is poised to be the first erythropoietin (EPO


Sandoz v. Amgen - Biosimilars at the U.S. Supreme Court
  • K&L Gates
  • USA
  • July 6 2017

The U.S. Supreme Court unanimously decided Sandoz Inc., v. Amgen Inc., on Monday June 12, 2017, construing the Biologics Price Competition and